Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Cancer immunotherapy Stories

2013-06-02 23:01:05

A promising, new cancer immunotherapy combination treatment showing long term survival for patients with metastatic melanoma was highlighted today at the American Society of Clinical Oncology Annual Meeting in Chicago. (PRWEB) June 02, 2013 A promising, new cancer immunotherapy combination treatment showing long term survival for patients with metastatic melanoma was highlighted today at the American Society of Clinical Oncology Annual Meeting in Chicago. Results form a phase II study...

2013-06-02 23:00:29

Additional Data Released at ASCO Annual Meeting Shows More Promising Results for Immunotherapy as a Treatment Option in Melanoma Chicago, IL (PRWEB) June 02, 2013 Some of the most promising results ever seen in melanoma clinical trials were announced today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The drugs work by manipulating the immune system to increase anti-tumor immunity. Specifically, they target the program death-1 (PD-1) receptor pathway which...

2013-06-02 12:20:09

Contributed by Cancer Research Institute NEW YORK, June 2, 2013 /PRNewswire/ -- At six years old Emily Whitehead was only two weeks from a bone marrow transplant when her leukemia came back for a second time. (Photo: http://photos.prnewswire.com/prnh/20130602/LA24333) Emily, who goes by Emma, had been fighting acute lymphoblastic leukemia since she was five years old. With her second relapse, she and her parents were out of options -- until she was offered a place as the first...

2013-05-31 12:21:41

Studies Submitted to ASCO Demonstrate Immunogenic Superiority of AE37 Over All Other Peptide Cancer Vaccines WORCESTER, Mass. and TORONTO, May 31, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today highlighted advantages of its AE37 cancer vaccine and technology in the context of a positive cancer immunotherapy forecast recently issued by Citigroup analysts. The Company's wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com)...

2013-05-30 23:14:29

FDA Review in SITC's Journal for ImmunoTherapy of Cancer offers new insights into cancer immunotherapy product development & clinical evaluation. Milwaukee, WI (PRWEB) May 30, 2013 A picture of what the FDA is looking for in cancer immunotherapy product development appears in an extensive new review article published in the inaugural issue of the Journal for ImmunoTherapy of Cancer. Providing a US regulatory perspective on pre-clinical to first in man studies, the review is described...

2013-05-27 10:43:58

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ignore cancer cells. Regulatory T cells are immune cells that function to suppress the immune system response. In this issue of the Journal of Clinical Investigation, researchers led by Ronald Levy at Stanford University found that regulatory T cells that infiltrate tumors...

2013-05-22 16:25:31

Series of five webinars will discuss cutting-edge research and breakthroughs in immune treatments for cancers and ways to get involved in immunotherapy NEW YORK, May 22, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit organization committed to developing immune system-based cancer treatments, is holding a series of five webinars in June to talk about breakthroughs in cancer immunotherapy research and treatments as part of Cancer Immunotherapy...

2013-05-16 08:21:03

SHM-XEL platform to generate high thermostability antibodies for biodefense applications SAN DIEGO, May 16, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense applications. Under the terms of AnaptysBio's contract with the Science and Technology Corporation, AnaptysBio will be responsible for...

2013-05-09 23:45:40

The Cancer Research Institute (CRI) declares June “Cancer Immunotherapy Awareness Month” to increase awareness of cancer immunotherapy, a new class of cancer treatment that mobilizes the immune system to fight the disease and represents the most immediate hope for curing patients with any type of cancer. The month will feature educational webinars offered free to the public from top experts in cancer immunotherapy, and a Wear White for a Cure Day on June 7. New York, NY (PRWEB)...

2013-04-16 20:23:11

LAWRENCEBURG, Ind., April 16, 2013 /PRNewswire/ -- PDS Biotechnology Corporation today presented a summary of the company's preclinical data on its lead cancer immunotherapy PDS0101 at the World Vaccine Congress in Washington DC. The product is based on the company's ground-breaking and proprietary Versamune(TM) nanotechnology vaccine platform. PDS Biotechnology also announced that the company's Investigational New Drug (IND) application had been granted by the FDA allowing PDS0101 to be...